Director Dealing
20/07/2023 09:54
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230720:nRST6659Ga&default-theme=true
RNS Number : 6659G Alliance Pharma PLC 20 July 2023
20 July 2023
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Director Dealing
Alliance Pharma plc (AIM: APH), the international healthcare group, has been
notified that Jo LeCouilliard, the non-executive Chair of the Company,
purchased 40,957 ordinary shares of 1.0p each in the Company ("Ordinary
Shares") at a price of 48.8 pence per share on 20(th) July 2023.
Following this transaction, (i) Jo LeCouilliard's total beneficial interest in
the Company is 40,957 Ordinary Shares, representing 0.008% of the Company's
issued share capital.
The notification below, made in accordance with the requirements of the EU
Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them.
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name Jo LeCouilliard
2 Reason for the notification
a) Position/status Non-executive Chair, PDMR
b) Initial notification /Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Alliance Pharma Plc
b) Legal Entity Identifier 213800RYIWZA4Q5WPZ13
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary shares of 1 pence each
Identification code
GB0031030819
b) Nature of the transaction Purchase of shares
c) Currency GBP
d) Price(s) and volume(s) Price(s) Volume(s)
48.8 40,957
e) Aggregated information
- Aggregated volume 40,957 Ordinary Shares, bought at a price of 48.8 pence per share, totalling
£ 19,987.02.
- Price
- Aggregated total
f) Date of the transaction 20 July 2023
g) Place of the transaction London Stock Exchange, AIM
For further information:
Alliance Pharma plc + 44 (0)1249 466966
Cora McCallum, Head of Investor Relations & Corporate Communications + 44 (0)1249 705168
ir@allianceph.com (mailto:ir@allianceph.com)
Buchanan + 44 (0)20 7466 5000
Mark Court / Hannah Ratcliff
alliancepharma@buchanan.uk.com (mailto:alliancepharma@buchanan.uk.com)
Numis Securities Limited (Nominated Adviser and Joint Broker) + 44 (0)20 7260 1000
Freddie Barnfield / Duncan Monteith / Sher Shah
Investec Bank plc (Joint Broker) + 44 (0)20 7597 5970
Patrick Robb / Maria Gomez de Olea
About Alliance
Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our
purpose is to empower people to make a positive difference to their health and
wellbeing by making our trusted and proven brands available around the world.
We deliver organic growth through investing in our priority brands and
channels, in related innovation, and through selective geographic expansion to
increase the reach of our brands. Periodically, we may look to enhance our
organic growth through selective, complementary acquisitions.
Headquartered in the UK, the Group employs around 285 people based in
locations across Europe, North America, and the Asia Pacific region. By
outsourcing our manufacturing and logistics we remain asset-light and focused
on maximising the value we can bring, both to our stakeholders and to our
brands.
For more information on Alliance, please visit our
website: www.alliancepharmaceuticals.com
(http://www.alliancepharmaceuticals.com/)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHVBLBLXDLEBBL